JX7 Stock Overview
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.20 |
| 52 Week High | US$18.00 |
| 52 Week Low | US$9.25 |
| Beta | 0.94 |
| 11 Month Change | 1.54% |
| 3 Month Change | 17.86% |
| 1 Year Change | -16.98% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| JX7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.7% | -2.5% | -1.3% |
| 1Y | -17.0% | -8.4% | 7.4% |
Return vs Industry: JX7 underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: JX7 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| JX7 volatility | |
|---|---|
| JX7 Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JX7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: JX7's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 2,200 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
Embecta Corp. Fundamentals Summary
| JX7 fundamental statistics | |
|---|---|
| Market cap | €775.75m |
| Earnings (TTM) | €66.93m |
| Revenue (TTM) | €1.07b |
11.4x
P/E Ratio0.7x
P/S RatioIs JX7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JX7 income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$375.70m |
| Gross Profit | US$743.20m |
| Other Expenses | US$673.50m |
| Earnings | US$69.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 66.42% |
| Net Profit Margin | 6.23% |
| Debt/Equity Ratio | -209.5% |
How did JX7 perform over the long term?
See historical performance and comparison